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The generation of peptides presented by MHC class I mole-
cules requires the proteolytic activity of the proteasome and/or
other peptidases. The processing of a short vaccinia virus-en-
coded antigen can take place by a proteasome-independent
pathway involving initiator caspase-5 and -10, which generate
antigenic peptides recognized by CD8 T lymphocytes. In the
present study, comparing single versus double enzyme diges-
tions by mass spectrometry analysis, both qualitative and quan-
titative differences in the products obtained were identified.
These in vitro data suggest that each enzyme can use the degra-
dation products of the other as substrate for new cleavages, indi-
cating concerted endoproteolytic activity of caspase-5 and -10.
The proteasome is the primary and major proteolytic com-
plex involved in the cytosolic generation of epitopes fromnewly
synthesized pathogen proteins (1). This multicatalytic endo-
protease regulates the degradation of cellular proteins and pro-
duces a broad diversity of peptides. The immune systemhas not
evolved specialized proteolytic mechanisms for cytosolic anti-
gen processing but utilizes this phylogenetically ancient cata-
bolic pathway tomark pathogen-infected cells. Among the vast
array of peptides generated by the proteasome, a small fraction
constitutes the correct epitope or NH2-terminally extended
precursors, both of which can be utilized for MHC class I anti-
gen presentation. These epitope precursor peptides may be
N-terminally trimmed by aminopeptidases in the cytosol (2) or
after transport by TAP transporters to the lumen of the endo-
plasmic reticulum (3, 4). Lastly, binding to nascentMHC class I
molecules generates the antigenic complex recognized at the
infected cell surface by specific CD8 cytotoxic T lymphocytes.
In addition to proteasome-independent and TAP-indepen-
dent antigen processing secretory pathways (reviewed in Refs.
5, 6), the endoproteolytic activity of tripeptidyl peptidase II was
described as the first enzymatic activity able to generate patho-
gen-derived peptides in the cytosol when proteasomes are
inhibited (7, 8). Endoproteolytic activities of caspases (9), nar-
dilysin (10), and insulin-degrading enzyme (11) were impli-
cated recently in antigen processing. In the caspase study, an
additional proteasome-independent pathway for antigen pro-
cessing of the 19-amino acid-long gene product encompassing
murine CMV immunodominant epitope was characterized (9).
This pathway operates when apoptosis is induced by vaccinia
virus infection and implies the proteolytic activity of caspase-5
and -10 in the generation of viral antigenic peptides recognized
by CD8 cytotoxic T lymphocytes. More than 14 different
members are included in the mammalian family of caspases
(12), a kind of cytoplasmic cysteine proteases, some of which
are involved in inflammatory responses, whereas others are
essential for programmed cell death in a variety of species (12).
They can be detected in many different types of cells undergo-
ing apoptosis, regardless of their origin or the death stimulus,
including infection by many pathogens (13, 14). Initiator
caspases are the first to be activated, followed by effector
caspases, which act on cellular target molecules. They are syn-
thesized as zymogens with no or very low intrinsic enzymatic
activity. Direct aggregation of initiator caspases after the trig-
gering stimulus is sufficient to promote self-processing to gen-
erate active heterotetramers. Downstream caspases are then
activated proteolytically by initiator caspases in a cascade fash-
ion. When studied separately, two human initiator caspases, 5
and 10, processed the 19-mer encompassing the CMV epitope
in vitro, with each generating a variety of peptidic products (9).
We are interested in the study of possible cooperative effects of
both cysteine proteases in the antigen processing of this mini-
protein. This in vitro study shows qualitative as well as quanti-
tative differences in the products obtained from single caspase
digestions when compared with the mixture of both enzymes,
indicating a concerted action of caspase-5 and -10.
EXPERIMENTAL PROCEDURES
Reagents—Ac-WEHD-CHO, Ac-YVAD-CHO, and Ac-
DEVD-CHO caspase inhibitors used in control digestions were
purchased from the Peptide Institute (Osaka, Japan). m19
(MDIGAYPHFMPTNLAGDPY) peptide was synthesized in
an Applera (Foster City, CA) peptide synthesizer model 433A,
purified, and confirmed to be homogeneous by HPLC analysis.
The sequence of the cytomegalovirus natural 9pp89 epitope is
in boldface type. The nonamer 9pp89 with the sequence YPH-
FMPTNL is the murine CMV immunodominant epitope pre-
sented by H-2Ld (15).
Caspase Digestion Assays—Caspase-5 and -10 were ex-
pressed selectively in bacteria and purified as described (9, 16).
m19 digestions by caspases were performed as follows (9, 16);
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them19peptide, dissolved in dimethyl sulfoxide, was incubated
overnight at room temperature with a concentration of 2 M of
each caspase in 0.2 ml. When the mixture of both enzymes was
used, identical amounts of each enzymewere added in the same
final volume. Digestion time of 16 h was chosen to mimic time
of exposure of m19 to proteases in infected cells (9). The final
concentration of m19 was 0.5 mM, and the incubation buffer
consisted of 0.1MHEPES, pH7.5, 10% sucrose, 0.1%CHAPS, 10
mM DTT. After incubation, the samples were frozen at 70 °C
until further analysis. Similar experiments in presence of 0.2
mM WEHD-CHO or 2 mM YVAD-CHO (to inhibit caspase-5),
or 0.2mMDEVD-CHO(to block caspase-10 activity), were used
as caspase specificity controls. Control digestions in the pres-
ence of caspase inhibitors did not reveal any cleavage product
other than the m19 substrate (data not shown). The data are
mean values of three independent experiments.
MS—Aliquots of total digestions were dried and dissolved in
10 l of 0.5% acetic acid in water and sequenced by quadrupole
ion trap microHPLC (Biobasic C18 column 150  0.18 mm,
Thermo Fisher Scientific, San Jose, CA) electrospray MS/MS2
in a Deca XP LCQ mass spectrometer (Thermo Fisher Scien-
tific). The eluents used were as follows: A, 0.5% acetic acid in
water; B, 80% acetonitrile containing 0.5% acetic acid. The gra-
dient was 0–40% B in 24 min, 40–100% in 5 min, at a flow rate
of 1.5 l/min1. We used the MS/MS mode focused to each
hypothetical parental peptide with an isolation width (m/z) of
1.5Da (9, 17). The charge and themass of the ionic species were
determined by high resolution sampling of the mass/charge
rank. Collision energy and ion-precursor resolution were
improved to optimize the fragmentation spectrum. All identi-
fied peptides were sequenced by MS/MS fragmentation.
RESULTS AND DISCUSSION
As a first step, caspase-5 and -10were isolated and purified as
reported previously (9, 16).Next, them19 synthetic peptidewas
incubated with either caspase-5, caspase-10, or a mixture of
both caspases. Each total digestion was analyzed extensively by
MS/MS to detect all relevant products, i.e. potential epitope
precursors as well as the final epitope. Microliquid chromatog-
raphy coupled to MS/MS was used, and the analysis was
restricted to each theoretical parent ion and followed by man-
ual interpretation (9, 17). This technique was employed as it
increases peptide detection and optimizes the identification of
generated peptides because it can resolve isomeric products
generated from this miniprotein that include the CMV immu-
nodominant epitope, such as A9pp89 and 9pp89A or GA9pp89
and 9pp89AG, as we reported previously in the analysis of anti-
gen processing of this m19 synthetic peptide by proteasomes
(17). Peptides such as DIGA9pp89AG and IGA9pp89AGD also
have the same m/z value. In addition, as the m19 sequence
presents two Met residues that are oxidized easily, located at
the N terminus and at residue 10, all relevant processed pep-
tides could also appear as the oxidized molecular ion. As a
consequence, some peptides with oxidized Met such as
DIGA9pp89AGD and other not oxidized ones, such as
MDIGA9pp89AG, present identicalm/z values but can be dis-
tinguished by this technique (17).
As shown in Table 1, caspase-5 or -10 produced a broad
spectrum of processed peptides. As we reported previously (9),
these products were unexpected given the canonical enzyme
specificity. Caspase-5 or -10 generated either the 2DIGAYPH-
FMPTNLAGD17 or the 6YPHFMPTNLAGDPY19 peptides as
major cleavage products, respectively. The latter peptide exhib-
its the exactN-terminal Tyr of 9pp89 epitope. The secondmost
abundant peptide produced by caspase-5 was the N-terminal
extended peptide 1MDIGAYPHFMPTNL14, which has the
correct C-terminal Leu. Caspase-10 also produces low amounts
of the exact optimally antigenic 6YPHFMPTNL14 9pp89 nona-
mer. In addition, several peptides were identified in these single
caspase digestions. Lastly, the proteolytic efficiency of
caspase-10 was 10-fold higher than that of caspase-5 (Table 1).
Control digestions in the presence of caspase-5- or caspase-10-
specific inhibitors did not reveal any antigenic peaks other than
the m19 substrate (data not shown). This lack of other peptidic
products in these control digestions, as well as the diversity of2 The abbreviations used is: MS/MS, tandem mass spectrometry.
TABLE 1
Digestion pattern of m19 synthetic peptide 1MDIGAYPHFMPTNLAGDPY19 with purified caspase-5 and/or -10 analyzed by mass spectrometry
Peptide sequencea
Correct C
terminus Residuesb Caspase-5 Caspase-10 Caspase-5 and -10
YPHFMPTNL Yes 6–14 0c 0.74 0.41
AYPHFMPTNL Yes 5–14 0 2.43 0.81
YPHFMPTNLA 6–15 0 2.14 1.22
AYPHFMPTNLA 5–15 0.36 0 20.00
AYPHFMPTNLAG 5–16 0 1.00 0.30
YPHFMPTNLAGD 6–17 0 0 0.11
AYPHFMPTNLAGD 5–17 0.66 1.32 0
DIGAYPHFMPTNLA 2–15 0 2.40 2.02
DIGAYPHFMPTNLAG 2–16 0.55 1.42 0
IGAYPHFMPTNLAGD 3–17 0.59 1.14 0.66
MDIGAYPHFMPTNL Yes 1–14 1.19 0 22.20
YPHFMPTNLAGDPY 6–19 0 68.19 36.95
MDIGAYPHFMPTNLA 1–15 0.50 0 2.36
DIGAYPHFMPTNLAGD 2–17 3.66 0 0
MDIGAYPHFMPTNLAGDP 1–18 0.79 0 0
Total 8.29 80.77 87.03
a Sequences of cleavage products were identified by mass spectrometry. The sequence of the cytomegalovirus natural 9pp89 epitope is in boldface.
b The peptidic products increased in the digestion with the mixture of both caspases with respect to individual digestions are indicated in boldface. Peptides identified in in-
dividual digestions but not in the mixture of caspases are underlined.
c Intensity of spectrum normalized to the average base peak ( 106). Data are means of three different experiments.
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products generated by digestion with each enzyme, speaks for
the purity of the caspase preparations.
When the mixture of both caspase-5 and -10 was used as
enzymatic source, the 6YPHFMPTNLAGDPY19 peptide,
detected in the single caspase-10 digestion, also was the most
abundant product (Table 1). Other cleavage products produced
by the isolated activity of either caspase-5 or caspase-10 were
also identified, including the optimal antigenic 9pp89 nonamer.
Unexpectedly, a minor amount of peptide 6YPHFMPTN-
LAGD17 was identified in the mixture of caspases but not in
individual digestions with each single enzyme (Table 1, bold-
face text). Two additional cleavage products, 1MDIGAYPH-
FMPTNL14 and 5AYPHFMPTNLA15, were much more effi-
ciently generated by the combined action of the two caspases
than in the individual digestions (Table 1, boldface text). Lastly,
four peptides found in caspase-5 digestions, two of which also
were produced by caspase-10, were not detected in the experi-
ment with the two caspases (Table 1, underlined text). In sum-
mary, the collection of peptidic products generated by themix-
ture of caspase-5 and -10 is different than the simple addition of
individual caspase products.
To study the specificity of mixed versus single digestions the
frequency of each cleavage was calculated. As shown in Fig. 1,
cleavage of Met1–Asp2 and Asp17–Pro18 peptide bonds was
preferred by caspase-5. In contrast, cleavage between Ala5 and
Tyr6, which is the C-terminal residue of the immunodominant
9pp89 epitope, was preferred largely by caspase-10 (Fig. 1). This
was also the most prominent cleavage when the mixture of
caspases was used. But in addition, significant cleavages around
the immunodominant 9pp89 core (Gly4–Ala5, Leu14–Ala15,
and Ala15–Gly16) were found abundantly in the mixture of
caspases but almost not in each single digestion. Thus, the drop
in the frequency of Met1–Asp2 and Asp17–Pro18 cleavage
points typical of caspase-5, the increase of these three new
cleavage points as well as the identification of the new product
6YPHFMPTNLAGD17 in the mixed enzyme condition indi-
cate a cooperative activity of both caspase-5 and -10 in antigen
processing of the 19-amino acid-long peptide encompassing
the CMV 9pp89 epitope.
In addition, somepeptides having the correctC terminus and
N-terminal extensions of the optimal 9pp89 nonamer were
identified in either individual or combined caspase digestions
(Table 1). These precursors could be susceptible to trimming by
ERAP enzymes in living cells can thus be relevant for antigen
presentation. This is especially important for the murine CMV
pp89 immunodominant epitope, which must be transported to
the ER lumen as N-terminal extended precursors because the
final 9pp89 ligand is very inefficiently translocated by TAP (18).
Small amounts of N-terminal extended precursors such as
5AYPHFMPTNL14 and 1MDIGAYPHFMPTNL14 were de-
tected in individual caspase digestions (Fig. 2). After a com-
bined caspase-5 and -10 exposure, the generation of 1MDI-
GAYPHFMPTNL14 peptide was enhanced greatly to turn into
the secondmajor product of digestion (Table 1 and Fig. 2). This
resembled the activity of the proteasome on the 19-mer sub-
strate (17, 19) and suggests that the combined activity of both
enzymes could improve the efficiency of antigen presentation
by the proteasome-independent caspase-mediated pathway
reported previously (9).
Caspase-5 and -10 are both initiator caspases of proinflam-
matory (20) and apoptotic (21) pathways induced by vaccinia
infection. Even though physical association has not been
reported, our data suggest that they can use their respective
degradation products as a substrate for new cleavages. Initial
cooperation between separate enzymes in antigen processing
was described for furin and amino- and carboxypeptidases in
the secretory pathway (22). In addition, similar to our present
report, a concerted peptide trimming by human ERAP1 and
ERAP2 aminopeptidases was required for the digestion of a
15-mer peptide with an amino-terminal extension of six resi-
dues (23), which is a natural epitope endogenously processed
from theHIV gp160 glycoprotein (24). Thus, cooperative activ-
ity of related and even unrelated (10) enzymesmay not be a rare
event in antigen processing of specific epitopes, and its rele-
vance must be evaluated in future studies with other epitopes.
REFERENCES
1. Kloetzel, P.M., andOssendorp, F. (2004)Curr. Opin. Immunol. 16, 76–81
2. Rock, K. L., York, I. A., and Goldberg, A. L. (2004) Nat. Immunol. 5,
670–677
FIGURE 1. Comparison of cleavage patterns of m19 synthetic peptide
with purified caspase-5 and/or -10. The m19 synthetic peptide was
digested with the purified caspase-5 (Casp 5; open bars), caspase-10 (Casp 10;
gray bars), or with a mixture of the two enzymes (Casp 5 and 10; filled bars) and
analyzed by MS/MS as in Table 1. The bars indicate the relative frequency of
each cleavage, deduced from the amounts of identified peptide products
shown in Table 1. Amounts are depicted relative to the most abundant prod-
uct within each digestion.
FIGURE 2. Comparative analysis of the generation of N-terminal
extended precursors of the final size epitope. The m19 synthetic peptide
was digested with the purified caspase-5 (Casp 5), caspase-10 (Casp 10), or
with a mixture of the two enzymes (Casp 5 and 10) and analyzed by MS/MS as
in Table 1. The code used of detected products is as follows: 6 –14 peptide
(filled bars), 5–14 peptide (open bars), 1–14 peptide (thick hatched bars), and
total (thin hatched bars).
Concerted Antigen Processing by Caspases
16912 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 19 • MAY 13, 2011
3. Hammer, G. E., Kanaseki, T., and Shastri, N. (2007) Immunity. 26,
397–406
4. Saveanu, L., Carroll, O., Hassainya, Y., and van Endert, P. (2005) Immunol.
Rev. 207, 42–59
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danz, J., Reddehase, M. J., and Koszinowski, U. H. (1988) J. Virol. 62,
3965–3972
16. Garcia-Calvo, M., Peterson, E. P., Rasper, D. M., Vaillancourt, J. P., Zam-
boni, R., Nicholson, D.W., andThornberry, N. A. (1999)Cell DeathDiffer.
6, 362–369
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